Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [3] Company Overview - Ventyx Biosciences specializes in medicinal chemistry, structural biology, and immunology to discover differentiated small molecule therapeutics for conditions with high unmet medical needs [3] - The company's lead portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases [3] - Ventyx's inflammatory bowel disease portfolio features tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials [3] Upcoming Event - Company executives will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 2:40 to 3:10 PM ET [2] - A webcast of the presentation will be available on the Ventyx website, with a replay accessible for ninety days post-event [2]